Attendee search 

The Company is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company has two FDA approved products: DUEXIS® and RAYOS®.  DUEXIS®s is a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill.  DUEXIS is indicated for the relief of signs and symptoms of rheumatoid arthritis (“RA”) and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications. In June 2012, the Company began expanding its commercial organization and expects to almost double its original field force size by the end of the third quarter of 2012, to approximately 150 field sales representatives. Also in June 2012, the Company engaged Mallinckrodt LLC, the pharmaceutical business of Covidien plc, on a non-exclusive basis to co-promote DUEXIS in the U.S. and entered into an exclusive collaboration, license and supply agreement with Grünenthal S.A. for the potential commercialization of DUEXIS in Latin America.

The Company’s second product, RAYOS®, known as LODOTRA® outside the U.S., is a proprietary delayed release formulation of low-dose prednisone that is currently marketed in Europe by its distribution partner, Mundipharma International Corporation Limited (“Mundipharma”), for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. In addition, the Company has granted to Mundipharma commercialization rights to LODOTRA in Asia and Latin America. On July 26, 2012, the FDA approved RAYOS for the treatment of a broad range of diseases, including RA, polymyalgia rheumatica (“PMR”), psoriatic arthritis (“PsA”), ankylosing spondylitis (“AS”), asthma and chronic obstructive pulmonary disease (“COPD”). The Company anticipates the launch of RAYOS in the United States in the fourth quarter of 2012. The Company’s strategy is to commercialize its products in the U.S. and to enter into licensing or additional distribution agreements for commercialization of its products outside the U.S.

 

AlloCure is a Boston-based biotechnology company developing AC607, an allogeneic mesenchymal stem cell therapy for the treatment acute kidney injury (AKI) with potential applications in other grievous illnesses. 

Building on the success of a phase 1 clinical trial, AlloCure has initiated ACT-AKI, a randomized, multicenter, double-blind, placebo-controlled phase 2 trial in cardiac surgery subjects with post-operative AKI. Currently, there are no available treatment options for patients with AKI other than supportive care. AC607 represents the first application of a cell therapy to alter the course of this life threatening condition.

Fully Integrated Pharmaceutical Operations

Purdue provides partner companies with extensive expertise in discovery, clinical development, project management, regulatory affairs, manufacturing, marketing, and sales. A dedicated Alliance Management function ensures that every dimension and detail involved in our collaborations gets the attention required. Purdue has regulatory expertise and experience in gaining approval from the U.S. Food and Drug Administration (FDA). Our national U.S. sales and marketing organization has the critical mass and know-how to commercialize new products quickly and effectively.

Global Reach

Purdue Pharma and its independent associated companies (including the Mundipharma/Napp companies) have a presence in more than 30 countries and a staff of more than 5,000.  Each of these international companies is a leader within their respective market for key therapeutic areas.

Expertise in Pain Management

Purdue has long-standing expertise in pain management and has transformed clinical practice to better serve the needs of patients with pain. We have conducted extensive pharma industry research into the development of analgesics that provide safe and effective pain relief to patients. We work extensively with physicians, opinion leaders, and patient advocacy groups to ensure that pain is appropriately recognized and treated.

Purdue and Shionogi & Co., Ltd., one of Japan’s largest research-based pharmaceutical companies, are collaborating on the discovery and development of new, non-opioid pain medications to treat pain. The research, which targets cellular receptors known to modulate pain responses, is being conducted jointly at Purdue’s research center in Cranbury, New Jersey, and Shionogi’s laboratories in Osaka, Japan.

Purdue has an exclusive U.S. licensing and co-promotion agreement with Labopharm Inc. of Laval, Canada for Ryzolt® (tramadol HCl extended-release tablets), an extended release formulation of tramadol.

Expanding into Related Therapeutic Areas

Purdue has an exclusive license and collaboration agreement with Transcept Pharmaceuticals, Inc. to commercialize Intermezzo® (zolpidem tartrate sublingual tablet), a product for one type of insomnia.

Additionally, Purdue Pharma L.P. and its independent company, Mundipharma International Corporation Limited, entered into a global partnership with Infinity Pharmaceuticals, Inc. to advance the research, development, and commercialization of Infinity’s discoveries and early clinical programs in oncology (outside the United States) and neuropathic pain (worldwide).

Purdue’s Therapeutic Areas of Interest

Purdue’s licensing strategy seeks to identify late-stage products within the following therapeutic areas:

• Pain management – both non-opioids and opioids
• Sleep disorders
• Gastrointestinal disorders